Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12644276 | 0.93 | SIGMAR1 (0.34) | CHRNA7CHRM5ADRA2CMETAP1HPGD | |
| SCHEMBL12644781 | 0.74 | HTR2A (0.34) | ADRA2C | |
| SCHEMBL12644809 | 0.72 | ADRA2A (0.36) | ADRA2CTAAR1 | |
| SCHEMBL12644799 | 0.72 | ADRA2A (0.36) | ADRA2CTAAR1 | |
| SCHEMBL12644338 | 0.70 | — | — | |
| SCHEMBL2034212 | 0.69 | ALDH1A1 (0.30) | HPGD | |
| SCHEMBL18723610 | 0.68 | ALDH1A1 (0.33) | LMNAHPGDTSHRSMN1; SMN2 | |
| SCHEMBL18723903 | 0.68 | ALDH1A1 (0.33) | LMNAHPGDTSHRSMN1; SMN2 | |
| SCHEMBL2041691 | 0.67 | HTR6 (0.33) | ADRA2CHPGDTAAR1 | |
| SCHEMBL12644296 | 0.64 | CYP19A1 (0.48) | ADRA2CMETAP1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220062229-A1 | METHODS OF TREATING SCHIZOPHRENIA | SUNOVION PHARMACEUTICALS INC. (US) | 2022-03-03 | — | — | US | disclosed |
| US-11129807-B2 | Methods of treating schizophrenia | SUNOVION PHARMACEUTICALS INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200129477-A1 | METHODS OF TREATING SCHIZOPHRENIA | SUNOVION PHARMACEUTICALS INC. (US) | 2020-04-30 | — | — | US | disclosed |
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3252057-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2507245-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9351954-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351954-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160083399-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PGI DRUG DISCOVERY LLC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083399-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PGI DRUG DISCOVERY LLC. | 2016-03-24 | — | — | US | disclosed |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | PSYCHOGENICS INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | PSYCHOGENICS INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CHRNA7 360/4885CHRM5 355/4885ADRA2C 438/4885 |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CHRNA7 360/4885CHRM5 355/4885ADRA2C 438/4885 |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CHRNA7 360/4885CHRM5 355/4885ADRA2C 438/4885 |
| US-20220062229-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | CHRNA7 25/4885CHRM5 52/4885ADRA2C 372/4885 |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | GRIN2C, NLN, COMT | CHRNA7 360/4885CHRM5 355/4885ADRA2C 438/4885 |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | GRIN2C, NLN, COMT | CHRNA7 360/4885CHRM5 355/4885ADRA2C 438/4885 |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CHRNA7 360/4885CHRM5 355/4885ADRA2C 438/4885 |
| US-20160083399-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CHRNA7 360/4885CHRM5 355/4885ADRA2C 438/4885 |
| US-20200129477-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | CHRNA7 25/4885CHRM5 52/4885ADRA2C 372/4885 |
| US-11129807-B2 | Methods of treating schizophrenia | CHAT, GAP43, GRIN2A | CHRNA7 25/4885CHRM5 52/4885ADRA2C 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.